Recombinant ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) decreases vascular calcification and prevents osteomalacia in a rat model of chronic kidney disease.
Saved in:
| Title: | Recombinant ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) decreases vascular calcification and prevents osteomalacia in a rat model of chronic kidney disease. |
|---|---|
| Authors: | O'Brien K; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Laurion L; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Sullivan C; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Howe J; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Lynch AM, Cheng Z, Schrier D; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Husson H; Research and Development, Inozyme Pharma, Boston, MA 02210, United States., Sabbagh Y; Research and Development, Inozyme Pharma, Boston, MA 02210, United States. |
| Source: | JBMR plus [JBMR Plus] 2025 Apr 16; Vol. 9 (6), pp. ziaf065. Date of Electronic Publication: 2025 Apr 16 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101707013 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4039 (Electronic) Linking ISSN: 24734039 NLM ISO Abbreviation: JBMR Plus Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2473-4039 |
|---|---|
| DOI: | 10.1093/jbmrpl/ziaf065 |
